Protara rises on dosing patient in bladder cancer drug study

Protara Therapeutics

24/03/2022 14:18

** Shares of drugmaker  TARA.O  rise 2.9% to $5.56
    ** Co says it has dosed first patient in early-stage study
evaluating its experimental cell-based therapy, TARA-002, for
treatment of non-muscle invasive bladder cancer (NMIBC)
 urn:newsml:reuters.com:*:nGNX85DHNT
    ** NMIBC is cancer found in tissue that lines the inner
surface of the bladder that has not spread into the bladder
muscle
    ** Bladder cancer is the sixth most common cancer in U.S.,
with NMIBC representing about 80% of bladder cancer diagnoses -
TARA
    ** Stock down 17.6% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))